Quality Payment Program Measures Data |
Back to Merit-based Incentive Payment System |
Measure ID | NQF ID | National Quality Strategy Domain | Title | High Priority | Measure Type | Submission Methods | Speciality Measure Sets | |
---|---|---|---|---|---|---|---|---|
ASPS5 | Patient Safety | Breast Reconstruction: Return to OR | Outcome | Registry | Details | |||
ASPS7 | Patient Safety | Rate of Blood Transfusion for Patients Undergoing Autologous Breast Reconstruction | Outcome | Registry | Details | |||
ASPS8 | Communication and Care Coordination | Coordination of Care for Patients Undergoing Breast Reconstruction | Process | Registry | Details | |||
ASPS9 | Efficiency and Cost Reduction | Length of Stay Following Autologous Breast Reconstruction | Outcome | Registry | Details | |||
CAP10 | Effective Clinical Care | Blood Laboratory Samples for Potassium Determination with Hemolysis Drawn in ED | Intermediate Outcome | Registry | Details | |||
CAP11 | Communication and Care Coordination | Accurate Human Epidermal Growth Factor Receptor 2 (HER2) Tumor Evaluation and Repeat Evaluation in Patients with Breast Carcinoma | Process | Registry | Details | |||
CAP12 | Communication and Care Coordination | Accurate Human Epidermal Growth Factor Receptor 2 (HER2) Tumor Evaluation and Repeat Evaluation in Patients with Gastroesophageal Adenocarcinoma | Process | Registry | Details | |||
CAP13 | Communication and Care Coordination | Anaplastic Lymphoma Kinase (ALK) Biomarker Testing to Inform Clinical Management and Treatment Decisions in Patients with Non-small Cell Lung Cancer | Process | Registry | Details | |||
CAP15 | Communication and Care Coordination | BRAF Biomarker Testing to Inform Clinical Management and Treatment Decisions in Patients with Metastatic Colorectal Adenocarcinoma | Process | Registry | Details | |||
CAP16 | Communication and Care Coordination | Epidermal Growth Factor Receptor (EGFR) Biomarker Testing to Inform Clinical Management and Treatment Decisions in Patients with Non-small Cell Lung Cancer | Process | Registry | Details | |||
CAP17 | Communication and Care Coordination | FMS-like Tyrosine 3-Internal Tandem Duplication (FLT3-ITD) Biomarker Testing to Inform Clinical Management and Treatment Decisions in Patients with Acute Myeloid Leukemia | Process | Registry | Details | |||
CAP18 | Communication and Care Coordination | Mismatch Repair (MMR) or Microsatellite Instability (MSI) Biomarker Testing to Inform Clinical Management and Treatment Decisions in Patients with Primary or Metastatic Colorectal Carcinoma | Process | Registry | Details | |||
CAP19 | Communication and Care Coordination | ROS 1 Biomarker Testing to Inform Clinical Management and Treatment Decisions in Patients with Non-small Cell Lung Cancer | Process | Registry | Details | |||
CAP20 | Communication and Care Coordination | High Risk HPV Testing and p16 Scoring in Surgical Specimens for Patients with Oropharyngeal Squamous Cell Carcinoma (OPSCC) | Process | Registry | Details | |||
CAP21 | Communication and Care Coordination | High Risk HPV Testing in Cytopathology Specimens for Patients with Oropharyngeal Squamous Cell Carcinoma (OPSCC) | Process | Registry | Details | |||
CAP22 | Communication and Care Coordination | Turnaround Time (TAT) - Biopsies | Process | Registry | Details | |||
CAP23 | Communication and Care Coordination | Cancer Protocol Elements and Turnaround Time for Carcinoma and Carcinosarcoma of the Endometrium | Process | Registry | Details | |||
CAP24 | Communication and Care Coordination | Cancer Protocol Elements and Turnaround Time for Carcinoma of the Intrahepatic Bile Ducts | Process | Registry | Details | |||
CAP25 | Communication and Care Coordination | Cancer Protocol Elements and Turnaround Time for Carcinoma of the Pancreas | Process | Registry | Details | |||
CAP26 | Communication and Care Coordination | Cancer Protocol Elements and Turnaround Time for Hepatocellular Carcinoma | Process | Registry | Details |